Morphine

Concomitant use increases risk of respiratory depression due to actions at different CNS receptor sites.

Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monitor closely for respiratory depression and sedation.

Combined use of baclofen injection (intrathecal) and epidural morphine may result in hypotension and dyspnea.

Combined use with morphine (particularly epidural morphine) may result in hypotension and dyspnea.

Opioid agonist delays and reduces clopidogrel absorption, decreasing exposure to metabolites. Consider parenteral antiplatelet agent in acute coronary syndrome.

Opioid agonist that delays and reduces clopidogrel absorption, decreasing exposure to active metabolites. Consider parenteral antiplatelet agent in ACS patients.

Coadministration may cause respiratory depression and sedation, sometimes resulting in death. Patients should be observed for CNS depression signs.

Concomitant use increases risk of respiratory depression and accentuates sedative effect. Monitor closely for respiratory depression and sedation.

Concomitant use increases risk of respiratory depression and sedation. Opioids interact at mu receptors while benzodiazepines act at GABA A sites, creating additive CNS depression.

Concomitant use increases risk of respiratory depression due to actions at different CNS receptor sites. Sedative effect of midazolam is accentuated.

Concomitant use increases risk of respiratory depression and accentuates sedative effect. Monitor closely for respiratory depression and sedation.

May increase anesthetic/sedative effects and cardiorespiratory depression; can result in pronounced decreases in blood pressure and cardiac output.

May reduce induction dose requirements and increase anesthetic/sedative effects with pronounced decreases in systolic, diastolic, mean arterial pressures and cardiac output.

Opioid agonist delays and reduces absorption of ticagrelor and its active metabolite through slowed gastric emptying.

Opioids increase risk of serotonin syndrome when used with citalopram. Monitor for signs and symptoms of serotonin syndrome.

Opioids increase risk of serotonin syndrome when used concomitantly with citalopram. Monitor for signs and symptoms of serotonin syndrome.

HORIZANT taken with morphine causes increased somnolence/sedation, dizziness, and nausea compared with either drug alone.

Cationic drug eliminated by renal tubular secretion with potential for interaction with metformin by competing for common renal tubular transport systems.

CHCs have been shown to decrease plasma concentrations of morphine.

Oral contraceptives may induce conjugation of morphine, increasing its clearance.

Oral contraceptives may induce conjugation of morphine, increasing its clearance and decreasing plasma concentrations.

Opioid agonists delay and reduce absorption of prasugrel's active metabolite, presumably due to slowed gastric emptying.

Opioid that increases risk of serotonin syndrome. Monitor for signs and symptoms during treatment initiation and dosage increases.

May increase serum concentration of trospium and/or morphine due to competition for renal tubular secretion. Careful patient monitoring is recommended.

Alvimopan does not significantly alter the pharmacokinetics of intravenous morphine or its metabolite morphine-6-glucuronide. No dosage adjustment necessary.